Videos

Learn how proactive prophylaxis makes subcutaneous amivantamab plus lazertinib more tolerable, cutting severe rash, nail issues and clot risk.

Identifying patients early is key for getting them into the CAR T-cell therapy pipeline, according to Saad Z. Usmani, MD, MBA, FACP, FASCO.

Learn how monthly subcutaneous amivantamab cuts clinic time, eases infusion capacity, and supports dose tweaks without sacrificing outcomes.

Jesus D. Anampa, MD, MS, discussed SEER database trends in chemotherapy use for older women with TBNC and explained the rationale for using breast cancer–free survival vs OS.

Philip Blumenfeld, MD, reviewed efficacy signals from a pooled analysis of Alpha DaRT in pancreatic cancer.

Philip Blumenfeld, MD, discussed the biological rationale and distinct mechanism of action of EUS-guided radium 224 Alpha DaRT in pancreatic adenocarcinoma.

The extended-release tablet formulation may help improve patient adherence to treatment, possibly representing a more convenient, patient-friendly dosing schedule, according to Naveen Pemmaraju, MD.

At ONS 2026, an oncology nurse specialist discussed the timing and pharmacy coordination required to administer a time-sensitive mitomycin gel.

This episode of The AI Oncology Revolution highlighted the nursing and APP teams and how they are leading the charge in AI implementation.

Monthly subcutaneous amivantamab plus lazertinib shows strong first-line EGFR NSCLC responses, fewer visits, and far fewer reactions.

Learn how clinicians choose first-line EGFR lung cancer therapy, weigh brain mets risk, and manage combo side effects for lasting benefit.

At ONS 2026, Leah R. Yeager, APR, emphasized that improved internal marketing can bridge the knowledge gap and connect patients with free yoga services.

Naomi Cazeau, MSN, ANP-BC, AOCNP, discussed how anemia and inflammation drive psychoneurological symptoms in patients with hematologic malignancies.

Hua-Jay Cherng, MD, suggested molecular genotyping could replace standard R-CHOP with targeted, less toxic treatments tailored to specific DLBCL subtypes.

Properly training staff members and ensuring patient education are critical to ensuring the outpatient use of bispecific antibodies in the community setting.

Linda Chan, MSN, RN, ONC, CMSRN, EBP-C, emphasized that patients should check with providers regarding the removal of larger heparin lines for flushes.

Hua-Jay Cherng, MD, described the “threefold” benefits of taking part in training programs among junior investigators in lymphoma.

According to Timothy A. Yap, MBBS, PhD, FRCP, there is an unmet need in oncology for treating patients with CCNE1, FBXW7, and PPP2R1A genomic alterations.

Muhammad Umair Mushtaq, MD, explains how TIL therapy offers a 30% response rate for patients with metastatic melanoma in whom prior treatments have failed.

Zoldonrasib has elicited good responses and progression-free survival in an area with a large unmet need, said Jonathan Wesley Riess, MD, MS.

Timothy A. Yap, MBBS, PhD, FRCP, presented data from the MYTHIC trial, demonstrating a 60% ORR at the RP2D in patients with CCNE1-amplified PROC.

New data show amivantamab+lazertinib boosts survival vs osimertinib in EGFR lung cancer, with Q4W subcutaneous dosing and side-effect tips.

New data show amivantamab plus lazertinib boosts survival and brain control in EGFR+ lung cancer, with convenient Q4W injection tips.

Muhammad Umair Mushtaq, MD, discussed the evolution of TIL therapy in melanoma, focusing on first-line treatment potential and immune fitness.

In this closing segment on advanced renal cell carcinoma, Dr. Ornstein synthesizes key themes from the case discussion, emphasizing how disease biology and clinical presentation guide second-line treatment decisions. He highlights that patients with early progression after frontline therapy represent a higher-risk group that often requires a more aggressive treatment approach.